Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.88 -24.14%
EPS Growth %: +39.4%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
MGYR, EACO, FMBH, More
EPS Growth %: +39.4%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
MGYR, EACO, FMBH, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $57.27 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aon CEO warns AI data centers carry insurance risks
- TAL International (TAL) PT Lowered to $11.50 at Jefferies
- Kidoz names Derek Sentner as chief revenue officer
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
